What is Chelation Therapy?
Chelation therapy is a medical treatment that uses specialized drugs (chelating agents) to bind and remove toxic metals from the body, primarily used for treating heavy metal poisoning and iron overload conditions like hemochromatosis and thalassemia. 1
Mechanism of Action
Chelating agents work by binding to metal ions through multiple coordination sites, forming stable complexes that can be safely excreted from the body. The effectiveness depends on:
- Denticity (number of binding sites): Hexadentate chelators bind all 6 coordination sites of iron, while bidentate bind 2 sites 2
- Lipophilicity and molecular charge - determines tissue penetration
- Selectivity for ferric (Fe³⁺) ions - minimizes interference with essential metals like copper and zinc 2
The goal is to neutralize toxic labile metal pools, prevent organ accumulation, and facilitate safe excretion without metal redistribution 2.
Primary Clinical Applications
Iron Overload Disorders
Chelation is used when phlebotomy (bloodletting) is contraindicated or insufficient 1:
- Hemochromatosis patients who cannot tolerate phlebotomy due to anemia or cardiac instability
- Juvenile hemochromatosis with life-threatening cardiac iron overload - combination therapy is often required 1
- Beta-thalassemia major from chronic transfusions 2
Heavy Metal Poisoning
Chelation is the preferred treatment for acute or chronic intoxication with lead, arsenic, mercury, and other toxic metals 3, 4. Recent evidence shows chelation effectively reduces bone lead stores in children with blood lead >25 µg/dL 5.
Common Chelating Agents
For Iron Overload
Deferoxamine (DFO) - Hexadentate, parenteral administration:
- Requires subcutaneous infusion via pump or IV infusion
- Short half-life (~20 minutes) necessitates continuous administration
- Side effects: injection site reactions, ophthalmologic/audiologic toxicity at high doses 2
Deferasirox (DFX) - Oral, most studied in hemochromatosis:
- Starting dose: 10 mg/kg daily (15 mg/kg caused excessive side effects)
- Reduced median ferritin by 75% over 48 weeks 1
- Requires monthly liver/renal monitoring, annual audiology/ophthalmology 1
Deferiprone (DFP) - Oral, tridentate:
- Dosed 3 times daily due to short half-life (1.5-2.5 hours)
- Critical warning: Risk of agranulocytosis (one fatal case reported in hemochromatosis patients with cardiac iron overload) 1
For Heavy Metal Poisoning
- CaNa₂EDTA - Most reliable and safer for occupational lead poisoning 4
- DMSA (dimercaptosuccinic acid) - Promotes renal metal excretion but limited intracellular access 3
- Dimercaprol - Older agent with significant side effects, largely replaced 3
Critical Safety Considerations
All iron chelation drugs are contraindicated in pregnancy and require dose adjustment in renal failure 1.
Monitoring requirements vary by agent:
- DFX: Monthly liver/renal function, baseline and annual audiology/ophthalmology 1
- DFO: Growth monitoring, ophthalmologic and audiological testing 2
- DFP: Close hematologic monitoring for agranulocytosis 1
Potential complications include:
- Renal dysfunction and electrolyte imbalances
- Infections (Yersinia, Klebsiella with DFO) 2
- Acute respiratory distress syndrome with excessive IV DFO 2
- Arthropathy and zinc depletion with DFP 2
Important Caveats
Chelation should only be prescribed by clinicians with expertise in these therapies 1. Patients requiring chelation for hemochromatosis should be referred to specialized centers 1.
Controversial use in cardiovascular disease: Despite the TACT trial showing modest benefits, TACT2 failed to confirm efficacy for reducing cardiovascular events in diabetic patients. Current evidence does not support routine chelation for coronary artery disease 6, 7.